Scientists Stop Memory Decay by Administering Nasal Therapy to Mice

April 22, 2022 10:22:10

According to estimates from the Centers for Disease Control and Prevention (CDC), around  6 million people in the United States suffer from Alzheimer’s disease and related dementias. Of the Americans afflicted with this debilitating condition, there are 200,000 people under 60 with early-onset Alzheimer’s.

Scientists believe that Alzheimer’s is caused when proteins build up abnormally in and around brain cells, either forming plaque around the brain cells or tangles within the cells. A protein called amyloid forms plaque around the cells while a protein called tau forms tangles in the cells. We still don’t know what leads to this buildup of proteins. This buildup results in a reduction in the movement of neurotransmitters between brain cells and causes areas of the brain to start shrinking, usually starting with the areas that handle memories.

More than a century after the disease was first described, we still don’t have a cure. As such, more than 50 million people worldwide live with Alzheimer’s and are forced to deal with symptoms including confusion, problems with writing or speaking and memory loss.

However, scientists from LSU Health New Orleans and Sweden’s Karolinska Institute have revealed findings that could point to a possible treatment for Alzheimer’s. For quite a while, scientists have suspected that neuro-inflammation plays a role in the development of the memory-loss disease. By nasally delivering a noninvasive compound with anti-inflammatory properties to test mice, the researchers were able to halt the memory decay that is associated with Alzheimer’s. The study results show that it is possible to use a noninvasive, intranasal delivery method to alleviate the symptoms of Alzheimer’s.

Furthermore, Dr. Tharick Pascoal, an assistant professor of psychiatry and neurology at the University of Pittsburg School of Medicine, says that the study “supports the idea” that medication with anti-inflammatory effects would have a protective, therapeutic effect rather than a harmful effect.

Although Pascoal wasn’t involved in this research, he was the lead author of a similar study that was conducted in 2021. He notes that while several studies have found that anti-inflammatory agents have the ability to halt the progression of Alzheimer’s disease in mice, the results have not been replicated in human trials.

He also states that the presence of amyloid plaques doesn’t always result in the development of Alzheimer’s, pointing to another possible cause. Recent studies have suggested that inflammation could be the elusive cause of Alzheimer’s. Pascoal posits that neuro-inflammation in the brain cells coupled with dysfunctional inflammation-related cells could trigger the development of Alzheimer’s disease.

Several companies are pursuing other options to manage these mental health conditions. For instance, Silo Pharma Inc. (OTCQB: SILO) is looking to merge traditional pharmaceutical approaches with cutting-edge psychedelic research in order to develop new medications that will offer better outcomes in the treatment of PTSD, Alzheimer’s and other neurological indications.

NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.